Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Eikon Therapeutics, Inc.

Ticker
EIKN
Sector
Industry
Report date
November 12, 2026
Valye AI Score

74

High visibility
Recent developments
Recent developments summary

Recent developments highlight Eikon's clinical trial progress, leadership changes, and financial reporting for Q3 2026.

Recent developments:
  • Eikon Therapeutics is conducting a Phase 2/3 melanoma trial for EIK1001, selecting a 0.60 mg/m² dose for the study [N5].
  • The company dosed the first patient in the Phase 2/3 TeLuRide trial for EIK1001 targeting NSCLC [N6].
  • Eikon submitted an IND application for EIK1006 in prostate cancer [N2].
  • The company is developing safer PARP1 cancer treatments with candidates EIK1003 and EIK1004 [N4].
  • Ching-Pin Chang was appointed Executive Vice President and Chief Scientific Officer in 2026 [N3].
  • Eikon reported a net loss of $86.1 million for Q3 2026 and plans to present new NSCLC data at the ASCO conference [N8].
  • Key cancer data from the melanoma trial is anticipated in 2029 [N1].
Overview

Eikon Therapeutics, Inc. operates in the biotechnology sector developing novel cancer therapies. Its pipeline includes candidates targeting melanoma, non-small cell lung cancer, prostate cancer, and PARP1-related cancers. The company is advancing clinical trials for EIK1001, EIK1003, EIK1004, and EIK1006, with ongoing regulatory submissions and patient dosing milestones. Leadership changes include the appointment of a new Chief Scientific Officer in 2026. Financially, Eikon maintains strong liquidity with significant cash and short-term investments relative to liabilities as of Q3 2026.

Executive summary

Eikon Therapeutics, Inc. is a clinical-stage biotech company focused on oncology drug development, with multiple clinical trials underway including Phase 2/3 studies for melanoma and NSCLC. The company reported a net loss of $86.1 million for Q3 2026 and holds substantial liquidity with a current ratio of 7.21 as of September 30, 2026. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for EIKN

Bull case model:

Eikon's advancement of multiple clinical trials, including Phase 2/3 studies for melanoma and NSCLC, demonstrates active pipeline progression. The submission of an IND for EIK1006 in prostate cancer and the development of safer PARP1 inhibitors indicate a diversified oncology portfolio. Strong liquidity provides financial flexibility to support clinical development and potential partnerships. Leadership appointments may enhance scientific and operational capabilities.

Bear case model:

Eikon reported a significant net loss of $86.1 million in Q3 2026, reflecting high R&D expenses typical of clinical-stage biotech firms without commercial products. The absence of disclosed revenue and market capitalization data limits financial transparency. Clinical trial outcomes remain uncertain, and delays or failures could impact pipeline value. The company operates in a highly competitive oncology space with regulatory and scientific risks inherent to drug development.

Moat:

Eikon Therapeutics' moat is based on its proprietary drug candidates targeting multiple cancer types and its clinical-stage pipeline, which includes novel approaches to PARP1 inhibition and immuno-oncology. The company's ability to advance clinical trials and secure regulatory approvals will be critical to establishing competitive differentiation. Its substantial liquidity supports ongoing R&D activities, but the absence of commercial products limits current revenue generation and competitive positioning.

Risks overview
Risks summary
The primary risk for Eikon Therapeutics is the uncertainty of clinical trial outcomes and the associated regulatory approvals necessary for commercialization.
Risks details:

• Clinical Trial Risk: The success of Eikon's drug candidates depends on positive clinical trial outcomes, which are inherently uncertain and subject to regulatory approval processes.
• Financial Risk: The company reported significant net losses and relies on its liquidity to fund operations; prolonged development timelines may require additional capital raising.
• Competitive Risk: Eikon operates in a competitive oncology market with numerous companies developing similar therapies, which may impact market adoption and pricing.

FINAL FORECAST FOR EIKN

Final take one line
Eikon Therapeutics is a clinical-stage biotech with active oncology trials and strong liquidity but faces typical clinical and financial risks of early-stage drug development.
Final take 12 to 24 month view

Business trends: Advancement of multiple oncology clinical trials including melanoma, NSCLC, and prostate cancer candidates; focus on PARP1 inhibitors.
Execution milestones: Patient dosing in Phase 2/3 trials, IND submissions, leadership appointments, and planned data presentations at major oncology conferences.
Key risks: Clinical trial outcome uncertainty, significant net losses requiring sustained funding, and competitive pressures in oncology therapeutics.

Valye AI Visibility Research Score

High visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

74
LLM visibility overview
LLM Visibility known facts
  • Eikon Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer treatments.
  • The company is conducting multiple clinical trials including a Phase 2/3 trial for EIK1001 targeting melanoma and non-small cell lung cancer (NSCLC).
  • EIK1001 is dosed at 0.60 mg/m² for the Phase 2/3 melanoma trial.
  • Eikon has submitted an Investigational New Drug (IND) application for EIK1006 in prostate cancer.
  • The company is developing PARP1 cancer treatments with candidates EIK1003 and EIK1004.
  • Eikon appointed Ching-Pin Chang as Executive Vice President and Chief Scientific Officer in 2026.
  • The company reported a net loss of $86.1 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$1.59 per share.
  • As of September 30, 2026, Eikon held $98.5 million in cash and equivalents and $363.2 million in short-term investments, totaling $478.1 million in current assets against $66.3 million in current liabilities, resulting in a current ratio of 7.21 and a cash ratio of 6.97.
  • Eikon reported dosing the first patient in the Phase 2/3 TeLuRide trial for EIK1001 in NSCLC.
  • The company plans to present new NSCLC data at the ASCO conference.
  • Key cancer data from the melanoma trial is anticipated in 2029.
  • Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Sources
Sources - Context summary

Generated 2026-11-12

Sources - Earning calls
Sources - Other context
  • Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Sources - SEC Filings
  • S1 | 2026-03-30 | 10-K
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-11-07 | www.nasdaq.com | Eikon Therapeutics Eyes 2027 Melanoma Trial Update, With Key Cancer Data Expected in 2029 | https://www.nasdaq.com/articles/eikon-therapeutics-eyes-2027-melanoma-trial-update-key-cancer-data-expected-2029
  • N2 | 2026-10-15 | www.nasdaq.com | Eikon Submits IND For EIK1006 In Prostate Cancer; Stock Up Over 8% | https://www.nasdaq.com/articles/eikon-submits-ind-eik1006-prostate-cancer-stock-over-8
  • N3 | 2026-09-03 | www.nasdaq.com | Eikon Therapeutics Appoints Ching-Pin Chang As Executive VP & Chief Scientific Officer | https://www.nasdaq.com/articles/eikon-therapeutics-appoints-ching-pin-chang-executive-vp-chief-scientific-officer
  • N4 | 2026-08-22 | www.nasdaq.com | Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004 | https://www.nasdaq.com/articles/eikon-therapeutics-eyes-safer-parp1-cancer-treatments-eik1003-eik1004
  • N5 | 2026-08-11 | www.nasdaq.com | Eikon Therapeutics Selects 0.60 Mg/m² Dose For Phase 2/3 EIK1001 Melanoma Trial | https://www.nasdaq.com/articles/eikon-therapeutics-selects-060-mg-m2-dose-phase-2-3-eik1001-melanoma-trial
  • N6 | 2026-07-27 | www.nasdaq.com | Eikon Doses First Patient In Phase 2/3 TeLuRide For EIK1001 For NSCLC; Stock Up | https://www.nasdaq.com/articles/eikon-doses-first-patient-phase-2-3-teluride-eik1001-nsclc-stock
  • N7 | 2026-07-14 | www.nasdaq.com | Eupraxia Pharmaceuticals Appoints New Technical Operations Heads; Co-Founder Malone Steps Down | https://www.nasdaq.com/articles/eupraxia-pharmaceuticals-appoints-new-technical-operations-heads-co-founder-malone-steps
  • N8 | 2026-05-12 | www.nasdaq.com | Eikon Reports Q1 Loss Of $83 Mln; To Present New Non-Small Cell Lung Cancer Data At The ASCO | https://www.nasdaq.com/articles/eikon-reports-q1-loss-83-mln-present-new-non-small-cell-lung-cancer-data-asco
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine